Natus Medical Announces Record 2008 Fourth Quarter and Full Year Results
SAN CARLOS, Calif.-- Natus Medical Incorporated (Nasdaq:BABY) today announced financial results for the three and twelve months ended December 31, 2008.
For the fourth quarter ended December 31, 2008, Natus reported revenue of $43.4 million, increasing 27% from $34.2 million reported for the fourth quarter of 2007. The Company reported net income of $6.3 million, or $0.22 per diluted share for the fourth quarter of 2008 compared to net income of $2.8 million, or $0.12 per diluted share reported in the fourth quarter of 2007, representing increases of 126% and 81% respectively.
For the year ended December 31, 2008, Natus reported revenue of $161.8 million, increasing 37% from $118.4 million reported for 2007. The Company reported net income of $17.5 million, or $0.66 per diluted share in 2008, compared to net income of $9.8 million, or $0.43 per diluted share in 2007, representing increases of 79% and 54%, respectively.
The Company's reported results for 2007 included acquisition-related charges associated with the acquisition of Xltek in November 2007. Non-GAAP net income excluding those charges was $3.8 million, or $0.17 per diluted share, and $10.8 million, or $0.47 per diluted share, for the three and twelve months ended December 31, 2007, respectively.
"Even though they increased significantly on a year over year basis, our results for the fourth quarter were impacted by the economic downturn and the resulting reduction in capital spending by our hospital customers that we first noticed in early December," said Jim Hawkins, President and Chief Executive Officer of the Company.
"At the same time, sales of disposable supplies used with our newborn hearing screeners were strong in the fourth quarter, and we expect continued growth throughout 2009 for these disposable supply products," added Hawkins. "Throughout 2008 we were able to increase the average selling price of our AABR disposable, and we look for this trend to continue throughout 2009, bringing our margin on this product more in line with the margins earned by other medical device companies on proprietary disposable products."
Hawkins also stated, "Our business model for the past four years has been driven by a combination of internal growth and accretive acquisitions. Because the current economic environment is very uncertain, we have taken an even more cautious approach in our evaluation of potential acquisition targets and of the terms under which we would engage in transactions. That being the case, we have held off on finalizing acquisitions that could potentially be consummated in the short term. However, we continue to engage in discussions with potential acquisition targets. Our strong balance sheet leaves us well positioned to be able to take advantage of future acquisition opportunities as they present themselves."
"Forecasting our future business has become much more difficult due to a combination of a seemingly accelerating worldwide economic downturn, growing unemployment in the United States and its impact on healthcare providers, the deteriorating condition of financial institutions and the resultant freezing of credit markets, and forecasts of reduced capital spending by hospitals," said Hawkins. "In addition, we are dealing with a fluctuating U.S. dollar that may affect our international business. With that said, we believe our strong market position and unique niche products, combined with our world class sales organization, should allow Natus to continue to gain market share even in these uncertain times."
As of December 31, 2008 the Company had cash, cash equivalents, and short-term investments of $57.0 million, stockholders' equity of approximately $227 million, and working capital of approximately $102 million.
Natus reiterated the financial guidance that it released on January 20, 2009. While the Company has attempted to be prudent and conservative in providing the following financial guidance, it stressed the difficultly of accurately forecasting results in the current unsettled economic environment.
For fiscal 2009, the Company expects revenue to range from $166 million to $170 million and earnings per share to range from $0.57 to $0.61. For the first quarter of 2009, the Company expects revenue to range from $37 million to $38 million and earnings per share to range from $0.06 to $0.08. This compares to revenue of $36.9 million and earnings per share of $0.11 reported in the first quarter of 2009.
While the Company is forecasting net income to be flat in 2009 compared to 2008, earnings per share for 2009 will be impacted by the stock offerings the Company completed in April and May 2008, where the Company issued an aggregate of 5,485,500 shares of its common stock and raised approximately $100 million. The effect of these offerings will be particularly significant to the comparison of results for the first two quarters of 2009 versus the same periods in 2008, as the new shares were outstanding for only a portion of the second quarter of 2008.
The Company's 2009 guidance is on a GAAP basis, including the impact of expensing employee equity-based compensation, which the Company believes will be approximately $3.5 million. The Company also expects to record approximately $4.3 million of amortization expense associated with acquired intangible assets. All earnings per share amounts are on a diluted basis.
Use of Non-GAAP Financial Measures
In addition to disclosing financial results calculated in accordance with GAAP, this release contains non-GAAP financial measures that exclude the effects of costs associated with the November 29, 2007 acquisition of Xltek, including hedging losses associated with funding the acquisition, a charge for in-process research and development, and employee-severance charges, all incurred in the fourth quarter of 2007. The Company believes that the presentation of results excluding these acquisition-related charges provides meaningful supplemental information to both management and investors that is indicative of the Company's core operating results. The Company also believes the in-process research and development charge is not indicative of resources devoted to ongoing research and development efforts. Therefore, the Company believes the non-GAAP financial measures facilitate comparison of operating results across reporting periods. A reconciliation between the Company's results of operations on a GAAP and non-GAAP basis for the periods reported is included as part of the condensed consolidated statements of operations at the end of the Company's financial results release.
The Company believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing the Company's performance and when planning, forecasting, and analyzing future periods. The non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated.
Natus has scheduled an investment-community conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time today (8:00 a.m. Pacific Time). Individuals interested in listening to the conference call may do so by dialing (866) 953-0762 for domestic callers, or (617) 399-3492 for international callers, and entering reservation code 79352876. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (888) 286-8010 for domestic callers, or (617) 801-6888 for international callers, and entering reservation code 14778289.
The conference call also will be available real-time via the Internet at http://investor.natus.com, and a recording of the call will be available on the Company's Web site for 90 days following the completion of the call.
About Natus Medical Incorporated
Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories.
Additional information about Natus Medical can be found at www.natus.com.
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include, but are not limited to, statements regarding anticipated revenue and profitability for the first quarter and full year 2009, our ability to gain market share in future periods, our ability to increase the average selling price of disposable supplies and our ability to return to historic revenue and earnings growth rates. These statements are predictions based on current estimates and assumptions of our management as of the date of this press release and involve known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Natus cannot provide any assurance that its future results will meet expectations implied by the forward-looking statements. Our future results could differ materially due to a number of factors, including the effects of competition, the demand for our products and services, the impact of adverse global economic conditions on our target markets, our ability to expand our sales in international markets, our ability to maintain current sales levels in a mature domestic market, our ability to control costs, our ability to acquire businesses on attractive terms, or at all, and risks associated with bringing new products to market and integrating acquired businesses. Natus disclaims any obligation to update information contained in any forward-looking statement.
More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2007, and its quarterly reports on Form 10-Q, and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) Three Months Ended Twelve Months Ended December December December December 2008 2007 2008 2007 Revenue $ 43,395 $ 34,234 $ 161,831 $ 118,374 Cost of revenue 15,717 12,646 60,933 43,100 Gross profit 27,678 21,588 100,898 75,274 Operating expenses: Marketing and selling 11,072 8,056 40,093 28,202 Research and development 3,616 3,569 15,576 15,645 General and administrative 4,537 3,854 19,746 15,214 Total operating expenses 19,225 15,779 75,415 59,361 Income from operations 8,453 5,809 25,483 15,913 Other income/(expense): Interest income 226 143 1,029 695 Interest expense 79 (235 ) (735 ) (235 ) Other income, net 883 (496 ) 1,848 (359 ) Total other income/(expense) 1,188 (588 ) 2,142 101 Income before provision for 9,641 5,221 27,625 16,014 income tax Provision for income tax 3,354 2,442 10,152 6,234 Net income (loss) $ 6,287 $ 2,779 $ 17,473 $ 9,780 Earnings (loss) per share: Basic $ 0.23 $ 0.13 $ 0.69 $ 0.45 Diluted $ 0.22 $ 0.12 $ 0.66 $ 0.43 Weighted-average shares used to compute Basic earnings per share 27,598 21,687 25,278 21,600 Diluted earnings per share 28,588 22,908 26,557 22,815
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES RECONCILIATION OF NON-GAAP ADJUSTMENTS (UNAUDITED) (in thousands, except per share amounts) Three Months Ended Twelve Months Ended December December December December 2008 2007 2008 2007 GAAP based results: Income before provision for income $ 9,641 $ 5,221 $ 27,625 $ 16,014 tax Non-GAAP adjustments: Acquired in-process research and - 300 - 300 (a) development Loss on hedging activities associated with funding the purchase - 732 - 732 (b) of Xltek Employee-severance costs - 361 - 361 (c) Non-GAAP income before provision for 9,641 6,614 27,625 17,407 income tax Provision for income tax, as 3,354 2,824 10,152 6,615 adjusted Non-GAAP net income $ 6,287 $ 3,790 $ 17,473 $ 10,792 Earnings per share: Basic $ 0.23 $ 0.17 $ 0.69 $ 0.50 Diluted $ 0.22 $ 0.17 $ 0.66 $ 0.47 Weighted-average shares used to compute Basic earnings per share 27,598 21,687 25,278 21,600 Diluted earnings per share 28,588 22,908 26,557 22,815 (a) Charges for acquired in-process research and development expense of $300 related to the acquisition of Xltek on November 29, 2007. Management believes that excluding these charges facilitates comparisons of Natus' core operating results across multiple reporting periods. (b) Loss from hedging activities to fund the purchase of Xltek in Canadian dollars resulting from execution of CAD forward contracts and pre-acquisition changes in the USD/CAD exchange rate. (c) Employee-severance costs associated with restructuring activities initiated in the fourth quarter 2007.
Source: Natus Medical Incorporated
Released February 26, 2009